TrialThe oncologist2026

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

Adel Mandl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.